News Releases

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 21, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced its management

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 2, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted ten newly-hired employees inducement options to purchase an aggregate of 94,000 shares of

- Regulatory filings planned for US, EU, UK and Japan to enable multiple 2025 commercial launches – - Development strategy refined for oral Factor XIIa program – - Organizational focus to drive results and set path to positive cash flow – CAMBRIDGE, Mass.

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 22, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that William C.

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced its management

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 2, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 65,000 shares of

– Delays in treating attacks lead to increased anxiety, quality of life issues, higher frequency of returning attacks, and suboptimal clinical outcomes in both on-demand and prophylaxis patients - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar.

– Full EAMS designation would allow treatment of patients with sebetralstat prior to receiving a Marketing Authorization from UK   – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 12, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company

- Sebetralstat Phase 3 KONFIDENT clinical trial met all endpoints and demonstrated a favorable safety profile as first oral on-demand therapy for hereditary angioedema - - CEO transition supports ongoing evolution into commercial company - CAMBRIDGE, Mass.

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 8, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of